

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2531324/publications.pdf>

Version: 2024-02-01

125
papers

21,937
citations

117453

34
h-index

16605

123
g-index

131
all docs

131
docs citations

131
times ranked

25418
citing authors

#	ARTICLE	IF	CITATIONS
1	Pan-cancer analysis combined with experiments explores the oncogenic role of spindle apparatus coiled-coil protein 1 (SPDL1). <i>Cancer Cell International</i> , 2022, 22, 49.	1.8	3
2	^{BMI} changes and the risk of lung cancer in male never-smokers: A prospective cohort study. <i>Cancer Medicine</i> , 2022, 11, 1336-1346.	1.3	8
3	Lung cancer risk prediction models based on pulmonary nodules: A systematic review. <i>Thoracic Cancer</i> , 2022, 13, 664-677.	0.8	16
4	Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 783495.	2.2	13
5	Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	6
6	Transmembrane Protein-Based Risk Model and H3K4me3 Modification Characteristics in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 828814.	1.3	6
7	Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. <i>BMC Medicine</i> , 2022, 20, 187.	2.3	28
8	^{PSC} subtyping based on ^{TTF} and p40 expression reveals distinct molecular characteristics and therapeutic strategies. <i>International Journal of Cancer</i> , 2022, 151, 717-729.	2.3	2
9	^{KRAS} G12D mutation drives immune suppression and the primary resistance of anti-PD-L1 immunotherapy in non-small cell lung cancer. <i>Cancer Communications</i> , 2022, 42, 828-847.	3.7	29
10	The prognostic value of tumor deposits and the impact on the TNM classification system in esophageal cancer patients. <i>Journal of Surgical Oncology</i> , 2021, 123, 891-903.	0.8	4
11	Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110069.	1.4	4
12	The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 562-568.	1.4	7
13	PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF- κ B/IL8 pathway. <i>Cell Death Discovery</i> , 2021, 7, 32.	2.0	38
14	^{PD-L1} and ^{CD47} co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1743-1751.	0.8	12
15	Association between pre-diagnostic serum albumin and cancer risk: Results from a prospective population-based study. <i>Cancer Medicine</i> , 2021, 10, 4054-4065.	1.3	20
16	Tumor-infiltrating CD8 ⁺ T cell is prognostic and predicts adjuvant chemotherapy benefit in patients with limited-stage small cell esophageal carcinoma. <i>Clinical and Translational Medicine</i> , 2021, 11, e456.	1.7	3
17	METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding. <i>Nature Communications</i> , 2021, 12, 3803.	5.8	74
18	LAMC1 upregulation via TGF β 2 induces inflammatory cancer-associated fibroblasts in esophageal squamous cell carcinoma via NF- κ B-CXCL1-STAT3. <i>Molecular Oncology</i> , 2021, 15, 3125-3146.	2.1	26

#	ARTICLE	IF	CITATIONS
19	S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis. <i>Clinical and Translational Medicine</i> , 2021, 11, e459.	1.7	26
20	Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 314.	7.1	2
21	RNA N ⁶ -methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential. <i>Clinical and Translational Medicine</i> , 2021, 11, e525.	1.7	18
22	A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 734-749.	1.4	2
23	Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 18-31.	1.3	8
24	TGF- β 2-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2. <i>Cell Death and Disease</i> , 2021, 12, 901.	2.7	17
25	The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors. <i>Aging</i> , 2021, 13, 1383-1409.	1.4	9
26	Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 745769.	2.2	3
27	Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. <i>Nature Communications</i> , 2021, 12, 6770.	5.8	105
28	Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 782106.	2.2	0
29	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110619.	1.4	3
30	An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer. <i>Cancer Cell International</i> , 2021, 21, 691.	1.8	5
31	The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. <i>Cancer Letters</i> , 2020, 470, 95-105.	3.2	193
32	The association between fasting blood glucose trajectory and cancer risk in Chinese population without diabetes. <i>International Journal of Cancer</i> , 2020, 147, 958-966.	2.3	7
33	Development of a risk score for colorectal cancer in Chinese males: A prospective cohort study. <i>Cancer Medicine</i> , 2020, 9, 816-823.	1.3	6
34	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. <i>Nature Communications</i> , 2020, 11, 4878.	5.8	27
35	ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells. <i>Cell Death and Disease</i> , 2020, 11, 853.	2.7	21
36	Lymph node dissection and recurrent laryngeal nerve protection in minimally invasive esophagectomy. <i>Annals of the New York Academy of Sciences</i> , 2020, 1481, 20-29.	1.8	19

#	ARTICLE	IF	CITATIONS
37	Combined detection of aneuploid circulating tumor-derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non-small-cell lung cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e128.	1.7	22
38	Response to comment on "Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma". <i>Cancer Letters</i> , 2020, 494, 5-6.	3.2	0
39	The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer. <i>Cell Death and Disease</i> , 2020, 11, 933.	2.7	9
40	An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 182.	7.1	21
41	Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma. <i>EBioMedicine</i> , 2020, 59, 102959.	2.7	51
42	A three-lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e156.	1.7	19
43	Monoacylglycerol Lipase Knockdown Inhibits Cell Proliferation and Metastasis in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 559568.	1.3	12
44	Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 681-694.	2.1	7
45	Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. <i>Cancer Letters</i> , 2020, 479, 31-41.	3.2	57
46	Development and validation of an immune-related prognostic signature in lung adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 5960-5975.	1.3	79
47	Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 821-841.	1.2	22
48	Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. <i>Oncologist</i> , 2020, 25, e701-e708.	1.9	23
49	Risk prediction model for lung cancer incorporating metabolic markers: Development and internal validation in a Chinese population. <i>Cancer Medicine</i> , 2020, 9, 3983-3994.	1.3	13
50	Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma. <i>Cancer Letters</i> , 2020, 483, 46-58.	3.2	28
51	Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific immune and metabolic state. <i>Cancer Science</i> , 2020, 111, 1876-1886.	1.7	16
52	Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non-small-cell lung cancer: A multicenter in vitro diagnostic clinical trial. <i>Cancer Science</i> , 2020, 111, 1739-1749.	1.7	11
53	Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. <i>Cancer Biology and Medicine</i> , 2020, 17, 768-781.	1.4	33
54	Enhanced expression of queuine tRNA-ribosyltransferase 1 (QTRT1) predicts poor prognosis in lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1658-1658.	0.7	5

#	ARTICLE	IF	CITATIONS
55	Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study. <i>Translational Lung Cancer Research</i> , 2020, 9, 2460-2468.	1.3	0
56	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. <i>Radiotherapy and Oncology</i> , 2019, 140, 159-166.	0.3	16
57	Metabolic Syndrome Components and the Risk of Colorectal Cancer: A Population-Based Prospective Study in Chinese Men. <i>Frontiers in Oncology</i> , 2019, 9, 1047.	1.3	14
58	PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3055-3065.	1.2	24
59	Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis. <i>Cancer Communications</i> , 2019, 39, 1-17.	3.7	23
60	Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response. <i>Cancer Letters</i> , 2019, 459, 86-99.	3.2	34
61	Knockdown of <i>KLF5</i> promotes cisplatin-induced cell apoptosis via regulating DNA damage checkpoint proteins in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1069-1077.	0.8	18
62	Stiffness heterogeneity-induced double-edged sword behaviors of carcinoma-associated fibroblasts in antitumor therapy. <i>Science China Materials</i> , 2019, 62, 873-884.	3.5	3
63	Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1391.	3.8	370
64	PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing. <i>Cancer Medicine</i> , 2019, 8, 2429-2441.	1.3	26
65	Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 761-768.	0.8	63
66	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. <i>JAMA Oncology</i> , 2019, 5, 696.	3.4	380
67	Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity. <i>Journal of Translational Medicine</i> , 2019, 17, 430.	1.8	5
68	The TGF β ² -Induced Long Non-coding RNA TBULC Promotes the Invasion and Migration of Non-small Cell Lung Cancer Cells and Indicates Poor Prognosis. <i>Frontiers in Oncology</i> , 2019, 9, 1340.	1.3	6
69	Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762. <i>Toxicology and Applied Pharmacology</i> , 2019, 365, 71-83.	1.3	10
70	Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study. <i>International Journal of Cancer</i> , 2019, 144, 2972-2984.	2.3	38
71	Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. <i>The Lancet Global Health</i> , 2018, 6, e555-e567.	2.9	907
72	TGF β ² -induced NKILA inhibits ESCC cell migration and invasion through NF κ B/MMP14 signaling. <i>Journal of Molecular Medicine</i> , 2018, 96, 301-313.	1.7	44

#	ARTICLE	IF	CITATIONS
73	Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 469-481.	1.1	3
74	Mammographic density and associated predictive factors for Chinese women. <i>Breast Journal</i> , 2018, 24, 444-445.	0.4	2
75	Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance. <i>Cell Death and Disease</i> , 2018, 9, 759.	2.7	69
76	Long non-coding RNA GAS5 is induced by interferons and plays an antitumor role in esophageal squamous cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 3157-3167.	1.3	22
77	Novel long noncoding RNA NMR promotes tumor progression via NSUN2 and BPTF in esophageal squamous cell carcinoma. <i>Cancer Letters</i> , 2018, 430, 57-66.	3.2	92
78	The TGF β -induced lncRNA TBILA promotes non-small cell lung cancer progression in vitro and in vivo via cis-regulating HGAL and activating S100A7/JAB1 signaling. <i>Cancer Letters</i> , 2018, 432, 156-168.	3.2	68
79	Aberrant methylation of EYA4 promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2018, 109, 1811-1824.	1.7	26
80	Cohort Profile: The China Metal-Exposed Workers Cohort Study (Jinchang Cohort). <i>International Journal of Epidemiology</i> , 2017, 46, dyw223.	0.9	29
81	Prognostic alternative mRNA splicing signature in non-small cell lung cancer. <i>Cancer Letters</i> , 2017, 393, 40-51.	3.2	214
82	Long non-coding RNA NKILA inhibits migration and invasion of non-small cell lung cancer via NF- κ B/Snail pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 54.	3.5	116
83	The association between fasting blood glucose and the risk of primary liver cancer in Chinese males: a population-based prospective study. <i>British Journal of Cancer</i> , 2017, 117, 1405-1411.	2.9	26
84	Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 6, e1356147.	2.1	69
85	Dynamic variation of histone H3 trimethyl Lys4 (H3K4me3) and heterochromatin protein 1 (HP1) with employment length in nickel smelting workers. <i>Biomarkers</i> , 2017, 22, 420-428.	0.9	4
86	Stair-Climbing Test Predicts Postoperative Cardiopulmonary Complications and Hospital Stay in Patients with Non-Small Cell Lung Cancer. <i>Medical Science Monitor</i> , 2017, 23, 1436-1441.	0.5	15
87	Prognostic factors in curatively resected pathological stage I lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2017, 9, 5267-5277.	0.6	12
88	KAT2A coupled with the β -KGDH complex acts as a histone H3 succinyltransferase. <i>Nature</i> , 2017, 552, 273-277.	13.7	301
89	Decreased 5-hydroxymethylcytosine levels correlate with cancer progression and poor survival: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 1944-1952.	0.8	32
90	MIR-652-3p is upregulated in non-small cell lung cancer and promotes proliferation and metastasis by directly targeting Lgl1. <i>Oncotarget</i> , 2016, 7, 16703-16715.	0.8	38

#	ARTICLE	IF	CITATIONS
91	Unilateral absence of pulmonary artery associated with contralateral lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, E942-E946.	0.6	8
92	Calcification of arteries supplying the gastric tube increases the risk of anastomotic leakage after esophagectomy with cervical anastomosis. <i>Journal of Thoracic Disease</i> , 2016, 8, 3551-3562.	0.6	22
93	AJUBA promotes the migration and invasion of esophageal squamous cell carcinoma cells through upregulation of MMP10 and MMP13 expression. <i>Oncotarget</i> , 2016, 7, 36407-36418.	0.8	35
94	Surgical Outcomes of Synchronous Multiple Primary Non-Small Cell Lung Cancers. <i>Scientific Reports</i> , 2016, 6, 23252.	1.6	44
95	Mitochondria-Translocated PKG1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. <i>Molecular Cell</i> , 2016, 61, 705-719.	4.5	319
96	Cancer statistics in China, 2015. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 115-132.	157.7	14,374
97	Reproductive factors and risk of type 2 diabetes in an occupational cohort of Chinese women. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1217-1222.	1.2	17
98	Transcriptome profiling of lncRNA and co-expression networks in esophageal squamous cell carcinoma by RNA sequencing. <i>Tumor Biology</i> , 2016, 37, 13091-13100.	0.8	36
99	Epidemiology of Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 439-445.	0.6	347
100	Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients. <i>Tumor Biology</i> , 2016, 37, 9323-9331.	0.8	81
101	Loss of 5-Hydroxymethylcytosine Is an Independent Unfavorable Prognostic Factor for Esophageal Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0153100.	1.1	22
102	National cancer incidence and mortality in China, 2012. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 1-11.	0.7	193
103	Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy. <i>Radiation Oncology</i> , 2015, 10, 142.	1.2	11
104	Xerophilusin B Induces Cell Cycle Arrest and Apoptosis in Esophageal Squamous Cell Carcinoma Cells and Does Not Cause Toxicity in Nude Mice. <i>Journal of Natural Products</i> , 2015, 78, 10-16.	1.5	23
105	A Prospective Follow-up Study of the Relationship between C-Reactive Protein and Human Cancer Risk in the Chinese Kailuan Female Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 459-465.	1.1	31
106	Postoperative Intensity-Modulated Radiotherapy Improved Survival in Lymph Node-Positive or Stage III Thoracic Esophageal Squamous Cell Carcinoma. <i>Oncology Research and Treatment</i> , 2015, 38, 97-102.	0.8	31
107	Histone Methylation in Nickel-Smelting Industrial Workers. <i>PLoS ONE</i> , 2015, 10, e0140339.	1.1	28
108	Dynamic Changes in DNA Damage and Repair Biomarkers with Employment Length among Nickel Smelting Workers. <i>Biomedical and Environmental Sciences</i> , 2015, 28, 679-82.	0.2	7

#	ARTICLE	IF	CITATIONS
109	Development and validation of clinical diagnostic models for the probability of malignancy in solitary pulmonary nodules. <i>Thoracic Cancer</i> , 2014, 5, 162-168.	0.8	16
110	LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. <i>Gut</i> , 2014, 63, 1700-1710.	6.1	385
111	A MicroRNA Signature Predicts Survival in Early Stage Small-Cell Lung Cancer Treated with Surgery and Adjuvant Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e91388.	1.1	39
112	Challenges to effective cancer control in China, India, and Russia. <i>Lancet Oncology</i> , The, 2014, 15, 489-538.	5.1	411
113	Genetic landscape of esophageal squamous cell carcinoma. <i>Nature Genetics</i> , 2014, 46, 1097-1102.	9.4	600
114	Nickel-exposed workers in China: a cohort study. <i>Biomedical and Environmental Sciences</i> , 2014, 27, 208-11.	0.2	15
115	A retrospective cohort mortality study in Jinchang, the largest nickel production enterprise in China. <i>Biomedical and Environmental Sciences</i> , 2014, 27, 567-71.	0.2	14
116	A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. <i>Medical Oncology</i> , 2013, 30, 343.	1.2	50
117	Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5136-5145.	3.2	37
118	Report of incidence and mortality in China cancer registries, 2009. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2013, 25, 10-21.	0.7	219
119	Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.008821.	2.5	52
120	The impact of positive cancer family history on the clinical features and outcome of patients with non-small cell lung cancer. <i>Familial Cancer</i> , 2011, 10, 331-336.	0.9	8
121	Application of video-assisted thoracic surgery in the standard operation for lung tumors. <i>Clinical Oncology and Cancer Research</i> , 2010, 7, 310-316.	0.1	0
122	Association Between Sputum Atypia and Lung Cancer Risk in an Occupational Cohort in Yunnan, China. <i>Chest</i> , 2009, 135, 778-785.	0.4	19
123	Clinical application of exclusive right-thoracic approach in surgery with or without laparotomy for mid-upper esophageal cancer. <i>Chinese Journal of Clinical Oncology</i> , 2008, 5, 64-66.	0.0	1
124	Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: Report of 549 cases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 82-90.	0.4	107
125	The Deubiquitinase USP13 Maintains Cancer Cell Stemness by Promoting FASN Stability in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5